1. Search Result
Search Result
Results for "

fallopian tube cancers

" in MedChemExpress (MCE) Product Catalog:

3

Inhibitors & Agonists

3

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P99377

    OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab)

    Notch Cancer
    Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer .
    Navicixizumab
  • HY-P99229
    Upifitamab
    2 Publications Verification

    XMT-1535; Upinitatug

    ADC Antibody Cancer
    Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Upifitamab
  • HY-185280

    HS-20089; GSK5733584

    Antibody-Drug Conjugates (ADCs) Cancer
    Mocertatug rezetecan (HS-20089; GSK5733584) is an antibody-drug conjugate (ADC) targeting B7-H4. Mocertatug rezetecan exhibits activity against platinum-resistant ovarian cancer. Mocertatug rezetecan is used for the research of advanced solid tumors, especially ovarian cancer and triple-negative breast cancer .
    Mocertatug rezetecan

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: